PE20050948A1 - CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV - Google Patents

CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV

Info

Publication number
PE20050948A1
PE20050948A1 PE2004000875A PE2004000875A PE20050948A1 PE 20050948 A1 PE20050948 A1 PE 20050948A1 PE 2004000875 A PE2004000875 A PE 2004000875A PE 2004000875 A PE2004000875 A PE 2004000875A PE 20050948 A1 PE20050948 A1 PE 20050948A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
carbamoil
inhibitors
trans
amino
Prior art date
Application number
PE2004000875A
Other languages
Spanish (es)
Inventor
Kota Asahina
Yuki Kitao
Satoru Kobayashi
Kenichi Matsui
Masaki Yamashita
Hisashi Shinkai
Toshio Taniguchi
Kazuhiro Tsutsumi
Tomohiro Oda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34317220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20050948A1 publication Critical patent/PE20050948A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE CARBAMOIL-AMINA DE FORMULA (I), EN DONDE R1 ES H, ALQUILO(C1-C6), CICLOALQUILO (C3-C12) OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), OPCIONALMENTE SUSTITUIDOS; R3 ES CICLOALQUILO(C3-C12) OPCIONALMENTE SUSTITUIDO; R4 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), HETEROCICLO SATURADO DE 3 A 7 MIEMBROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: ACIDO 2-{TRANS-4-[(S)-AMINO-(N-CICLOBUTIL-N-METILACARBAMOIL)METIL]CICLOHEXILMETOXIMETIL}BENZOICO, ACIDO 3-{TRANS-4-[(S)-AMINO-(N-CICLOBUTIL-N-METIL-CARBAMOIL)METIL]CICLOHEXILMETOXIMETIL-5-DIMETILAMINOBENZOICO, (2-METANOSULFONIL)FENILAMIDA DE ACIDO TRANS 4-[(S)-AMINO-(N-CICLOBUTIL-N-METILCARBAMOIL)METIL]CICLOHEXANOCARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA DIPEPTIDIL PEPTIDASA DPP-IV, POR LO QUE SON UTILES PARA EL TRATAMIENTO DE LA DIABETES TIPO II, OBESIDAD O SIMILARESREFERS TO COMPOUNDS DERIVED FROM CARBAMOIL-AMINE OF FORMULA (I), WHERE R1 IS H, ALKYL (C1-C6), OPTIONALLY SUBSTITUTED CYCLOALKYL (C3-C12), AMONG OTHERS; R2 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C12), OPTIONALLY SUBSTITUTED; R3 IS CYCLOALKYL (C3-C12) OPTIONALLY SUBSTITUTED; R4 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C12), SATURATED HETEROCYCLE OF 3 TO 7 MEMBERS, OPTIONALLY REPLACED. PREFERRED COMPOUNDS ARE: 2- {TRANS-4 - [(S) -AMINO- (N-CYCLOBUTYL-N-METHYLACARBAMOYL) METHYL] CYCLOHEXYLMETOXIMETHYL} BENZOIC ACID, 3- {TRANS-4 - [(S) -AMINO- ( N-CYCLOBUTYL-N-METHYL-CARBAMOYL) METHYL] CYCLOHEXYLMETOXIMETHYL-5-DIMETHYLAMINOBENZOIC, (2-METHANOSULFONYL) TRANS 4 ACID PHENYLAMIDE - [(S) -AMINO- (N-CYCLOBUTILBUTYL-N-METHYLOCAR) HEXYLBUTYL-N-METHYLOCARYL OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OF THE DIPEPTIDIL PEPTIDASE DPP-IV ENZYME, SO THEY ARE USEFUL FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, OR SIMILAR

PE2004000875A 2003-09-09 2004-09-09 CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV PE20050948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003317407 2003-09-09
JP2003395879 2003-11-26
JP2004114685 2004-04-08

Publications (1)

Publication Number Publication Date
PE20050948A1 true PE20050948A1 (en) 2005-12-16

Family

ID=34317220

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000875A PE20050948A1 (en) 2003-09-09 2004-09-09 CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV

Country Status (4)

Country Link
AR (1) AR046330A1 (en)
PE (1) PE20050948A1 (en)
TW (1) TW200530157A (en)
WO (1) WO2005025554A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL377847A1 (en) 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
AU2006285393A1 (en) * 2005-04-27 2007-03-08 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
JP2009533393A (en) 2006-04-12 2009-09-17 プロビオドルグ エージー Enzyme inhibitor
US20080114075A1 (en) * 2006-08-16 2008-05-15 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
JP5605844B2 (en) 2008-10-17 2014-10-15 塩野義製薬株式会社 Acetic acid amide derivatives having vascular endothelial lipase inhibitory activity
PE20120332A1 (en) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp PEPTIDE PROPHARS FROM THE GLUCAGON SUPERFAMILY BASED ON AMIDA
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2777108A1 (en) * 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
DK2545047T3 (en) 2010-03-10 2014-07-28 Probiodrug Ag Heterocyclic Inhibitors of Glutaminyl Cyclase (QC, EC 2.3.2.5)
MX2012011631A (en) 2010-04-06 2013-01-18 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto.
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
BR112013008100A2 (en) 2010-09-22 2016-08-09 Arena Pharm Inc "gpr19 receptor modulators and the treatment of disorders related thereto."
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP5941981B2 (en) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド Tricyclic sulfonamide compounds and methods for their production and use
EP2705035B1 (en) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2012154676A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Partially saturated tricyclic compounds and methods of making and using same
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
WO2014071369A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
EP2917197B1 (en) 2012-11-05 2019-06-05 Zafgen, Inc. Tricyclic compounds and methods of making and using same
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2017538678A (en) * 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． Immunomodulator
LT3262028T (en) 2014-12-17 2022-01-10 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
SI3310760T1 (en) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta(b)indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
US11142546B2 (en) 2016-04-04 2021-10-12 Research Triangle Institute Neuropeptide S receptor (NPSR) agonists
KR20190116416A (en) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. Compounds and Methods for Treating Primary Bile Cholangitis
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
US10683267B1 (en) * 2019-11-21 2020-06-16 King Abdulaziz University Antidiabetic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
SE9701245D0 (en) * 1997-04-04 1997-04-04 Bjoern Classon antivirals
CO5150173A1 (en) * 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
US6936606B2 (en) * 2001-10-02 2005-08-30 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases
AU2002357767C1 (en) * 2001-11-26 2009-03-19 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes

Also Published As

Publication number Publication date
TW200530157A (en) 2005-09-16
AR046330A1 (en) 2005-12-07
WO2005025554A3 (en) 2005-07-28
WO2005025554A2 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
PE20050948A1 (en) CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
PE20080362A1 (en) DERIVATIVES OF CYCLOHEXYLPIRAZOLE-LACTAM AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHIDROGENASE 1
ECSP088765A (en) AMINOTETRAHYDROPIRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
PE20060777A1 (en) INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
PE20060921A1 (en) PROCEDURE TO PREPARE CHIRAL 8- (3-AMINO-PIPERIDIN-1-IL) -XANTHINES
PE20081836A1 (en) PIPERIDINE DERIVATIVES AS INHIBITORS OF FATTY ACID SYNTHASE
PE20070367A1 (en) SPIROPIPERIDINE COMPOUNDS AS INHIBITORS OF THE BETA SECRETASE ENZYME
PE20050121A1 (en) TIENYL-HYDROXAMIC ACIDS, SUBSTITUTED REFERRED TO THE ENZYMATIC ACTIVITY OF HISTONE DESACETILASE
PE20081545A1 (en) SULFONAMIDE DERIVATIVES AS SYNTHASE FATTY ACID INHIBITORS
NI201100081A (en) AMINOTETRAHYDROPYRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASE - IV FOR THE TREATMENT OR PREVENTION OF DIABETES.
PE20090601A1 (en) PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS
PE20061490A1 (en) CYCLOHEXANOSULPHONYL DERIVATIVES AS INHIBITORS OF THE GLYCINE TRANSPORTER GLYT1
PE20060937A1 (en) SULFONYLBENZIMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 2 (CB2) AGONISTS
AR062797A1 (en) PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS.
AR053415A1 (en) DIPEPTIDIL PEPTIDASA IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF COMPOUNDS AND COMPOSITION
PE20060316A1 (en) PROLIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS
PE20090880A1 (en) HETEROCYCLIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
PE20081487A1 (en) NICOTINAMIDE DERIVATIVES AS INHIBITORS OF 11ßHSD1
PE20061353A1 (en) SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS
PE20071326A1 (en) VIRAL POLYMERASE INHIBITORS
PE20040898A1 (en) NEW COMPOUNDS DERIVED FROM PYRIMIDINE
AR073348A1 (en) CYCLE INHIBITORS OF 11 BETA-HYDROXIESTEROID DEHYDROGENASE 1
PE20120620A1 (en) DIHYDROPIRAZOLONES SUBSTITUTED AS INHIBITORS OF HIF-PROPIL-4-HYDROXYLASES
PE20050864A1 (en) HETEROCICLYLAMINE COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1
PE20080364A1 (en) SUBSTITUTED BIPHENYLCARBOXYL ACID AND ITS DERIVATIVES AS MODULATORS OF THE ACTIVITY OF THE GAMMA-SECRETASE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal